

NEWS RELEASE

SunOpta Announces Fourth Quarter and Fiscal 2023 Financial Results

2/28/2024

Revenue from continuing operations increased 13.7% to \$181.6 million, driven by volume growth

Loss from continuing operations of \$1.8 million, compared to \$0.4 million in the prior year

Adjusted EBITDA from continuing operations of \$22.3 million, an increase of 17.5%

Re-affirming 2024 outlook

MINNEAPOLIS--(BUSINESS WIRE)-- SunOpta Inc. ("SunOpta" or the "Company") (Nasdaq:STKL) (TSX:SOY), a U.S.-based global pioneer fueling the future of sustainable, plant-based foods and beverages, today announced financial results for the fourth guarter and fiscal year ended December 30, 2023.

All amounts are expressed in U.S. dollars and results are reported in accordance with U.S. GAAP, except where specifically noted.

Fourth Quarter 2023 highlights:

- Revenues of \$181.6 million increased 13.7% compared to \$159.8 million in the prior year period, driven by volume growth
- Gross profit margin was 14.1% on a reported basis. Adjusted gross margin1 was 17.3%, down 50-basis points from the prior year period, mainly due to the 80-basis point increase in depreciation related to new production equipment.
- Operating income of \$5.1 million increased 47.8% compared to \$3.4 million in the prior year period.
- Loss from continuing operations was \$1.8 million compared to \$0.4 million in the prior year period mainly due to an increase in interest expense partially offset by increased gross profit.
- Adjusted earnings1 from continuing operations of \$5.7 million increased 120% compared to \$2.6 million in

- the fourth quarter of 2022 mainly due to improved operating performance, partially offset by increases in interest expense and depreciation.
- Adjusted EBITDA1 from continuing operations increased by 17.5% to \$22.3 million, or 12.3% of revenues, compared to \$19.0 million and 11.9% of revenues in the prior year period.

"Our latest results provide validation of the powerful potential of our platform. We are a growth company in growing categories and are armed with an optimized product portfolio and high-quality base of leverageable assets that provide significant runway for continued growth," said Brian Kocher, Chief Executive Officer of SunOpta. "Fourth quarter revenues and Adjusted EBITDA exceeded expectations reflecting solid execution against our strategic priorities focused on operational excellence and growth. Volume was up double-digits and accelerated sharply from the third quarter, underscoring the strength of our competitive position and the broad-based demand we are seeing across our portfolio. Plant-based milks and fruit snacks continue to drive growth. We are gaining share with existing customers as well as adding new customers in both categories. In addition, our 330-milliliter protein shake business continues to ramp up aggressively, advancing our total addressable market expansion efforts. We are re-affirming our outlook for 2024 reflecting a high degree of confidence in the direction and trajectory of our business."

Fourth Quarter 2023 Results

Revenues increased 13.7% to \$181.6 million for the fourth quarter of 2023. The increase was driven by favorable volume/mix which was up 14.7% partially offset by a price reduction of 1.0% due to pass through of commodity prices. Volume/mix reflected broad based volume growth from oat milks and creamers, 330-milliliter protein shakes and teas, as well as increased sales volumes for fruit snacks, partially offset as expected, by lower external sales of plant-based ingredients, due to increased internal demand for oat base, as well as lower broth volumes.

Gross profit was \$25.6 million for the fourth quarter, compared to \$23.8 million in the prior year period. As a percentage of revenues, gross profit margin was 14.1% compared to 14.9% in the fourth quarter of 2022, a decrease of 80 basis points, as reported. Adjusted gross margin1 was 17.3% for the fourth quarter of 2023 compared to 17.8% in the fourth quarter of 2022. The 50-basis point decrease in adjusted gross margin reflected the impact of incremental depreciation of new production equipment for capital expansion projects partially offset by a positive mix shift in plant-based ingredients with increased internal use.

Operating income was \$5.1 million, or 2.8% of revenues in the fourth quarter of 2023, compared to operating income of \$3.4 million, or 2.1% of revenues in the fourth quarter of 2022. The increase in operating income was primarily driven by higher gross profit.

Loss from continuing operations was \$1.8 million for the fourth quarter of 2023 compared to \$0.4 million in the

prior year period. Diluted loss per share from continuing operations attributable to common shareholders (after dividends and accretion on preferred stock) was \$0.02 for the fourth quarter compared with diluted loss per share of \$0.01 in the prior year period.

Loss from discontinued operations was \$10.0 million or \$0.09 per diluted share in the fourth quarter of 2023 versus earnings of \$1.5 million or \$0.01 per diluted share in the year earlier period.

Adjusted earnings1 from continuing operations was \$5.7 million or \$0.05 per diluted share in the fourth quarter of 2023, compared to adjusted earnings from continuing operations of \$2.6 million or \$0.02 per diluted share in the fourth quarter of 2022 mainly due to improved operating performance, partially offset by increases in interest expense and depreciation.

Adjusted EBITDA1 from continuing operations was \$22.3 million or 12.3% of revenue in the fourth quarter of 2023 compared to \$19.0 million or 11.9% of revenue in the fourth quarter of 2022.

Please refer to the discussion and table below under "Non-GAAP Measures".

Balance Sheet and Cash Flow

As of December 30, 2023, SunOpta had total assets of \$669.4 million and total debt of \$263.2 million compared to total assets of \$855.9 million and total debt of \$308.5 million at fiscal 2022 year end. During the fourth quarter of 2023, cash provided by operating activities of continuing operations was \$12.0 million compared to \$7.3 million during the fourth quarter of 2022. The increase in cash provided mainly reflected improved operating performance, partially offset by increased working capital and the impact of higher start-up costs and cash interest expense. Investing activities of continuing operations consumed \$9.2 million of cash during the fourth quarter of 2023 down from \$26.4 million in the prior year, reflecting the completion of certain major capital projects, including the construction of our new plant-based beverage facility in Midlothian, Texas.

2024 Outlook2

For fiscal 2024, the Company is re-affirming its outlook and continues to expect strong growth in revenue and Adjusted EBITDA:

(\$ millions)	 2024 Outlook	Growth
Revenue	\$ 670 – 700	6% - 11%
Adj. EBITDA	\$ 87 - 92	11% - 17%

Conference Call

SunOpta plans to host a conference call at 5:30 P.M. Eastern time on Wednesday, February 28, 2024, to discuss the fourth quarter financial results. After opening remarks, there will be a question and answer period. Investors interested in listening to the live webcast can access a link on SunOpta's website at **www.sunopta.com** under the "Investor Relations" section or directly **here**. A replay of the webcast will be archived and can be accessed for approximately 90 days on the Company's website. This call may be accessed with the toll free dial-in number dial (888) 440-4182 or International dial-in number (646) 960-0653 using Conference ID: 8338433.

1 See discussion of non-GAAP measures

2 The Company has included certain forward-looking statements about the future financial performance that include non-GAAP financial measures, including Adjusted EBITDA. These non–GAAP financial measures are derived by excluding certain amounts, expenses or income, from the corresponding financial measures determined in accordance with GAAP. The determination of the amounts that are excluded from these non-GAAP financial measures is a matter of management judgment and depends upon, among other factors, the nature of the underlying expense or income amounts recognized in a given period. We are unable to present a quantitative reconciliation of the aforementioned forward-looking non-GAAP financial measures to their most directly comparable forward-looking GAAP financial measures because management cannot reliably predict all of the necessary components of such GAAP measures. Historically, management has excluded the following items from certain of these non-GAAP measures, and such items may also be excluded in future periods and could be significant amounts.

- Expenses related to the acquisition or divestiture of businesses or assets, including business development costs, integration costs, severance, retention costs and transaction costs;
- Start-up costs of new facilities and equipment;
- Charges associated with restructuring and cost saving initiatives, including but not limited to asset impairments, accelerated depreciation, severance costs and lease abandonment charges;
- Asset impairment charges and facility closure costs;
- Legal settlements or awards; and
- The tax effect of the above items.

About SunOpta Inc.

SunOpta (Nasdaq:STKL) (TSX:SOY) is a U.S.-based, global pioneer fueling the future of sustainable, plant-based food and beverages. Founded 50 years ago, SunOpta manufactures organic and specialty products sold through retail and foodservice channels. SunOpta operates as a manufacturer for leading natural and private label brands, and

also proudly produces its own brands, including **SOWN** ®, **Dream** ®, **West Life** TM. For more information, visit **www.sunopta.com**, and **LinkedIn**.

Forward-Looking Statements

Certain statements included in this press release may be considered "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation, which are based on information available to us on the date of this release. These forward-looking statements include, but are not limited to, our belief that our protein shake business will ramp aggressively, our expectation for strong growth in revenue and Adjusted EBITDA and our anticipated Revenue, Adjusted EBITDA, Revenue growth and Adjusted EBITDA growth for fiscal 2024. Generally, forward-looking statements do not relate strictly to historical or current facts and are typically accompanied by words such as "continues", "expect", "believe", "anticipate", "estimates", "can", "will", "target", "should", "would", "plans", "becoming", "intend", "confident", "may", "project", "intention", "might", "predict", "budget", "forecast" or other similar terms and phrases intended to identify these forward-looking statements. Forward-looking statements are based on information available to the Company on the date of this release and are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments including, but not limited to, the Company's actual financial results; our exit from, and use of proceeds from the divestiture of the assets and liabilities of, Frozen Fruit, uninterrupted operations and service levels to our customers; current customer demand for the Company's products; general economic conditions; continued consumer interest in health and wellness; the Company's ability to maintain product pricing levels; planned facility and operational expansions, closures and divestitures; cost rationalization and product development initiatives; alternative potential uses for the Company's capital resources; portfolio optimization and productivity efforts; the sustainability of the Company's sales pipeline; the Company's expectations regarding commodity pricing, margins and hedging results; procurement and logistics savings; freight lane cost reductions; yield and throughput enhancements; the cost of the frozen fruit recall; labor cost reductions; and the terms of our insurance policies. Whether actual timing and results will agree with expectations and predictions of the Company is subject to many risks and uncertainties including, but not limited to, potential loss of suppliers and customers as well as the possibility of supply chain, logistics and other disruptions; unexpected issues or delays with the Company's structural improvements and automation investments; failure or inability to implement portfolio changes, process improvements, go-to-market improvements and process sustainability strategies in a timely manner; changes in the level of capital investment; local and global political and economic conditions; consumer spending patterns and changes in market trends; decreases in customer demand; delayed or unsuccessful product development efforts; potential product recalls; potential additional costs associated with the frozen fruit recall; working capital management; availability and pricing of raw materials and supplies; potential covenant breaches under the Company's credit facilities; and other risks described from time to time under "Risk Factors" in the Company's Annual Report on Form 10-K and its

Quarterly Reports on Form 10-Q (available at **www.sec.gov**). Consequently, all forward-looking statements made herein are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized. The Company undertakes no obligation to publicly correct or update the forward-looking statements in this document, in other documents, or on its website to reflect future events or circumstances, except as may be required under applicable securities laws.

SunOpta Inc.
Consolidated Statements of Operations
For the quarters and years ended December 30, 2023 and December 31, 2022
(Unaudited)
(All dollar amounts expressed in thousands of U.S. dollars, except per share amounts)

	Quarter ended Year en					
	December 30,	December 31,	December 30,	December 31,		
	2023 \$	2022 \$	2023 \$	2022 \$		
Revenues	181,624	159,790	630,297	591,395		
Cost of goods sold	155,983	135,974	541,680	491,665		
Gross profit	25,641	23,816	88,617	99,730		
Selling, general and administrative expenses Intangible asset amortization Other expense, net Foreign exchange loss (gain)	19,597 446 475 66	19,605 446 243 101	78,000 1,784 455 110	78,469 1,784 1,651 (107)		
Operating income	5,057	3,421	8,268	17,933		
Interest expense, net	7,518	4,312	26,909	13,156		
Earnings (loss) from continuing operations before income taxes	(2,461)	(891)	(18,641)	4,777		
Income tax expense (benefit)	(709)	(464)	3,269	896		
Earnings (loss) from continuing operations Earnings (loss) from discontinued operations	(1,752) (9,982)	(427) 1,481	(21,910) (153,108)	3,881 (8,722)		
Net earnings (loss)	(11,734)	1,054	(175,018)	(4,841)		
Dividends and accretion on preferred stock	(429)	(830)	(1,981)	(3,109)		
Earnings (loss) attributable to common shareholders	(12,163)	224	(176,999)	(7,950)		
Basic and diluted earnings (loss) per share Earnings (loss) from continuing operations Earnings (loss) from discontinued operations Earnings (loss) attributable to common shareholders	(0.02) (0.09) (0.11)	(0.01) 0.01 0.00	(0.21) (1.34) (1.55)	0.01 (0.08) (0.07)		
Weighted-average common shares outstanding (000s) Basic Diluted	115,793 115,793	107,861 107,861	114,226 114,226	107,659 110,247		

6

SunOpta Inc.
Consolidated Balance Sheets
As at December 30, 2023 and December 31, 2022
(Unaudited)
(All dollar amounts expressed in thousands of U.S. dollars)

	December 30, 2023 \$	December 31, 2022 \$
ASSETS	*	<u> </u>
Current assets Cash and cash equivalents Accounts receivable Inventories Prepaid expenses and other current assets Income taxes recoverable Current assets held for sale	306 64,862 83,215 25,235 4,717 5,910	679 59,545 74,439 15,535 4,040 148,119
Total current assets	184,245	302,357
Restricted cash Property, plant and equipment, net Operating lease right-of-use assets Intangible assets, net Goodwill Deferred income taxes Other long-term assets	8,448 319,898 105,919 21,861 3,998 - 25,055	292,306 78,761 23,646 3,998 3,712 5,184 145,888
Non-current assets held for sale		
Total assets	669,424	855,852
LIABILITIES Current liabilities Accounts payable and accrued liabilities Notes payable Income taxes payable Current portion of long-term debt Current portion of operating lease liabilities Current liabilities held for sale	96,650 17,596 - 24,346 15,808	95,879 - 957 38,491 12,499 13,207
Total current liabilities	154,400	161,033
Long-term debt Operating lease liabilities Deferred income taxes	238,883 100,102 505	269,993 74,329
Non-current liabilities held for sale Total liabilities	493,890	3,228 508,583
Series B-1 preferred stock	14,509	28,062
SHAREHOLDERS' EQUITY Common shares Additional paid-in capital Accumulated deficit Accumulated other comprehensive income Total shareholders' equity	464,169 27,534 (332,687) 2,009	440,348 33,184 (155,688) 1,363 319,207
Total liabilities and shareholders' equity	669,424	855,852
rotal habilities and shareholders equity		<u> </u>

SunOpta Inc.
Consolidated Statements of Cash Flows
For the quarters and years ended December 30, 2023 and December 31, 2022
(Unaudited)
(Expressed in thousands of U.S. dollars)

		Quarter ended		Year ended
Decei	ember 30,	December 31,	December 30,	December 31,
	2023 \$	2022 \$	2023 \$	2022 \$

7

Earnings (loss) from discontinued operations	CASH PROVIDED BY (USED IN) Operating activities	(11.724)	1.054	(175.019)	(4.041)
Earnings (loss) from continuing operations (1,752) (427) (21,910) 3,881 Items not affecting cash: 2 305 417 1,398 1,601 Depreciation and amortization 8,166 6,219 31,039 23,047 Amortization of debt issuance costs 305 417 1,398 1,601 Deferred income taxes (282) (11,533) 3,978 (296) Stock-based compensation 1,584 - 1,584 - Loss on extinguishment of debt 1,584 - 1,584 - Other 927 2,003 707 3,825 Changes in operating assets and liabilities, net of divestitures 853 6,509 (24,999) (15,142) Net cash provided by operating activities of continuing operations 11,960 7,327 3,575 30,746 Net cash provided by operating activities of discontinued operations (8,853) (26,397) (46,125) (125,139) Investing activities (88,853) (26,397) (46,125) (125,139) Net cash provi	Net earnings (loss)	(11,734) (9,982)	1,054 1,481	(175,018) (153,108)	(4,841) (8,722)
Depreciation and amortization		(1,752)	(427)	(21,910)	3,881
Changes in operating assets and liabilities, net of divestitures 853 6,509 (24,999) (15,142) Net cash provided by operating activities of continuing operations 11,960 7,327 3,575 30,746 Net cash provided by (used in) operating activities of discontinued operations 4,431 27,513 14,844 60,575 Net cash provided by operating activities 4,431 27,513 14,844 60,575 Investing activities 4,431 27,513 14,844 60,575 Net cash provided by operating activities 4,431 27,513 14,844 60,575 Net cash property, plant and equipment (8,853) (26,397) (46,125) (125,139) Cash settlement of foreign currency forward contract (394) - (394) - (394) Proceeds from sale of property, plant and equipment 4,182 Net cash used in investing activities of continuing operations 91,636 6,383 90,551 14,133 Net cash provided by investing activities of discontinued operations 91,636 6,383 90,551 14,133 Net cash provided by (used in) investing activities 82,389 (20,014) 44,032 (106,824) Financing activities 180,015 16,710 199,855 90,907 Repayment of long-term debt 180,015 16,710 199,855 90,907 Repayment of of long-term debt (63,868) (6,528) (95,303) (20,085) Repayment of of the spayable (141,880) -	Items not affecting cash: Depreciation and amortization Amortization of debt issuance costs Deferred income taxes Stock-based compensation Loss on extinguishment of debt	8,166 305 (282) 2,789 1,584	6,219 417 (11,533) 4,139	31,039 1,398 3,978 11,778 1,584	23,047 1,601 (296) 13,830
Net cash provided by operating activities of continuing operations 11,960 7,327 3,575 30,746 Net cash provided by (used in) operating activities of discontinued operations 7,529 20,186 11,269 29,829 Net cash provided by operating activities 4,431 27,513 14,844 60,575 Investing activities 4,431 27,513 14,844 60,575 Investing activities 4,431 27,513 14,844 60,575 Additions to property, plant and equipment (8,853) (26,397) (46,125) (125,139) Cash settlement of foreign currency forward contract (394) -					
Net cash provided by operating activities Investing activities Additions to property, plant and equipment Cash settlement of foreign currency forward contract (394) Proceeds from sale of property, plant and equipment (9,247) Example 1 (26,397) Example 2 (26,397) Example 2 (26,397) Example 3 (26,397) Example 4 (26,397) Example 3 (26,397) Example 3 (26,397) Example 3 (26,397) Example 4 (26,397) Example 3 (26,397) Example 4 (394) Example 4 (394) Example 5 (38,531) Example 6 (38,638) Example 7 (32,97) Example 7 (32,97) Example 7 (32,97) Example 6 (38,638) Example 6 (38,638) Example 6 (38,638) Example 7 (38,638) Example 7 (38,97) Example 7 (3	Net cash provided by operating activities of continuing operations				
Investing activities Additions to property, plant and equipment Cash settlement of foreign currency forward contract Proceeds from sale of property, plant and equipment Ret cash used in investing activities of continuing operations Ret cash used in investing activities of discontinued operations Ret cash provided by (used in) investing activities Repayment of long-term debt Repayment of asset-based credit facilities Repayment of asset-based credit facilities Repayment of asset-based credit facilities Repayment of debt issuance costs Repayment of ontes payable Repayment of notes payable Repayment of notes payable Repayment of motes payable Repayment of ontes payable Repayment of ontes payable Repayment of ontes payable Repayment of cash dividends on preferred stock Repayment of cash dividends on preferred stock Repayment of cash dividends on preferred stock Ret cash provided by (used in) financing activities of continuing operations Ret cash provided by (used in) financing activities of discontinued operations Ret cash provided by (used in) financing activities of discontinued operations Ret cash provided by (used in) financing activities of discontinued operations Ret cash provided by (used in) financing activities of discontinued operations Ret cash provided by (used in) financing activities of discontinued operations Ret cash provided by (used in) financing activities of discontinued operations Re		(, ,	*		
Additions to property, plant and equipment Cash settlement of foreign currency forward contract (394) Proceeds from sale of property, plant and equipment Proceeds from notes payable Proceeds from notes payable Proceeds from the exercise of stock options and employee share purchases Payment of outer payable Proceeds from the exercise of stock options and employee share purchases Payment of withholding taxes on stock-based awards Payment of common share issuance costs Payment of common share issuance costs Payment of preferred stock issuance costs Payment of preferred stock issuance costs Payment of preferred stock issuance costs Payment of common share issuance costs Payment of preferred stock issuance costs Payment of common share issuance costs Pay		1, 13 1	27,313	1 1,0 1 1	00,373
Proceeds from sale of property, plant and equipment Net cash used in investing activities of continuing operations Net cash provided by investing activities of discontinued operations Net cash provided by (used in) investing activities Net cash provided by (used in) financing activities of continuing operations Net cash provided by (used in) financing activities of discontinued operations Net cash provided by (used in) financing activities Net cash provided by (used in) financing activities of continuing operations Net cash provided by (used in) financing activities of continuing operations Net cash provided by (used in) financing activities of continuing operations Net cash provided by (used in) financing activities of size of the period Cash, cash equivalents and restricted cash, beginning of the period October 10,247 10,243 10,251 10,263 10,247 10,243 10,251 10,243 10,251 10,263 10,251 10,251 10,251 10,251 10,251 10,251 10,251 10,263 10,251 10,251 10,263 10,251 10,251 10,251 10,251 10,263 10,251 10,251 10,263 10,251 10,263 10,251 10,263 10,251 10,263 10,251 10,263 10,251 10,263 10,251 10,263 10,263 10,263 10,263 10,263 10,263 10,263 10,263 10,263 10,	Additions to property, plant and equipment		(26,397)		(125,139)
Net cash used in investing activities of continuing operations Net cash provided by investing activities of discontinued operations Net cash provided by (used in) investing activities Net cash provided by (used in) investing activities Financing activities Increase (decrease) in borrowings under revolving credit facilities Borrowings of long-term debt Repayment of long-term debt Repayment of asset-based credit facilities (141,880) Payment of debt issuance costs (32,97) Proceeds from notes payable Repayment of increase payable Repayment of motes payable Repayment of withholding taxes on stock-based awards Payment of cash dividends on preferred stock Repayment of common share issuance costs (30,00) Repayment of preferred stock issuance costs (30,00) Repayment of common share issuance costs (30,00) Repayment of common share issuance costs (30,00) Repayment of preferred stock issuance costs (30,00) Repayment of preferred stock issuance costs (30,00) Repayment of common share issuance costs (30,00) Repayment of preferred stock issuance costs (30,00) Repayment of common share issuance costs (30,00) Repayment of common share issuance costs (30,00) Repayment of common share issuance costs (30,00) Repayment of cost issuance costs (30,00) Repayment of cost issuance costs (30,00) Repayment of cost issuance cost issuance cost issuance cost issuance issuance cost issuance cost issu	9 ,	(334)	-	(334)	4,182
Net cash provided by (used in) investing activities Financing activities Increase (decrease) in borrowings under revolving credit facilities Increase (accrease) under u			(26,397)		
Financing activities Increase (decrease) in borrowings under revolving credit facilities Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalents and restricted cash, beginning of the period Increase in cash, cash equivalent	Net cash provided by investing activities of discontinued operations				
Increase (decrease) in borrowings under revolving credit facilities Borrowings of long-term debt Repayment of long-term debt (63,868) (63,868) (65,28) (95,303) (20,085) Repayment of debt issuance costs (141,880) - (141,880)		82,389	(20,014)	44,032	(106,824)
Repayment of notes payable Proceeds from the exercise of stock options and employee share purchases Payment of withholding taxes on stock-based awards Payment of cash dividends on preferred stock Payment of common share issuance costs Payment of preferred stock issuance costs Payment of common share issuance costs Payment of cost (25,00) Payme	Increase (decrease) in borrowings under revolving credit facilities Borrowings of long-term debt Repayment of long-term debt Repayment of asset-based credit facilities Payment of debt issuance costs	180,015 (63,868) (141,880) (3,297)	16,710 (6,528)	199,855 (95,303) (141,880) (3,297)	90,907 (20,085)
Payment of preferred stock issuance costs Net cash provided by (used in) financing activities of continuing operations Net cash provided by (used in) financing activities of discontinued operations Net cash provided by (used in) financing activities of discontinued operations Net cash provided by (used in) financing activities (81,610) (7,279) (50,801) 46,701 Increase in cash, cash equivalents and restricted cash in the period (23,544) (34,637) (49,833) (50,801) (50,801) (50,801) (67,01) (7,279) (7,279) (7,279) (81,610) (7,279) (81,610)	Repayment of notes payable Proceeds from the exercise of stock options and employee share purchases Payment of withholding taxes on stock-based awards Payment of cash dividends on preferred stock	(51,291) 1,051 (283)	(27)	(84,447) 1,882 (9,404) (1,732)	(1,629)
Net cash provided by (used in) financing activities of continuing operations Net cash provided by (used in) financing activities of discontinued operations Net cash provided by (used in) financing activities Net cash provided by (used in) financing activities (81,610) (7,279) (50,801) 46,701 (2,464) (49,833) (49,833) (50,801) (7,279) (50,801) (7,279) (7,279) (7,279) (81,610) (8	,	-	(756)	(191)	(756)
Net cash provided by (used in) financing activities of discontinued operations Net cash provided by (used in) financing activities (81,610) (7,279) (50,801) 46,701 Increase in cash, cash equivalents and restricted cash in the period 5,210 220 8,075 452 Cash, cash equivalents and restricted cash, beginning of the period 3,544 459 679 227			19,068		96,534
Increase in cash, cash equivalents and restricted cash in the period Cash, cash equivalents and restricted cash, beginning of the period 3,544 459 670 2754	Net cash provided by (used in) financing activities of discontinued operations				
Cash, cash equivalents and restricted cash, beginning of the period 3,544 459 679 227			,	. , ,	
Cash, cash equivalents and restricted cash, beginning of the period					
	Cash, cash equivalents and restricted cash, beginning of the period Cash, cash equivalents and restricted cash, end of the period	8,754		8,754	

Non-GAAP Measures

<u>Adjusted Gross Margin</u>

The Company uses a measure of adjusted gross margin to evaluate the underlying profitability of its revenue-generating activities within each reporting period. This non-GAAP measure excludes non-capitalizable start-up costs included in cost of goods sold that are incurred in connection with capital expansion projects. Additionally, the Company's measure of adjusted gross margin may exclude other unusual items that are identified and evaluated on an individual basis, which due to their nature or size, the Company would not expect to occur as part of its normal business on a regular basis. The Company believes that disclosing this non-GAAP measure provides investors with a meaningful, consistent comparison of its profitability measure for the periods presented. However, the non-GAAP measure of adjusted gross margin should not be considered in isolation or as a substitute for gross margin calculated based on gross profit determined in accordance with U.S. GAAP.

The following table presents a reconciliation of adjusted gross margin from reported gross margin calculated in

	December 30,	Quarter ended December 31,	December 30,	Year ended December 31,
	2023	2022	2023	2022
Reported gross margin Start-up costs(a) Product withdrawal costs(b)	14.1% 1.3% 1.9%	14.9% 2.9% -	14.1% 3.0% 0.5%	16.9% 1.0%
Adjusted gross margin	17.3%	17.8%	17.6%	17.8%

Note: percentages may not add due to rounding.

Adjusted Earnings/Loss and Adjusted EBITDA

In addition to reporting financial results in accordance with U.S. GAAP, the Company provides additional information about its operating results regarding adjusted earnings/loss and adjusted earnings/loss before interest, taxes, depreciation and amortization ("Adjusted EBITDA"), which are not measures in accordance with U.S. GAAP. The Company believes that adjusted earnings/loss and adjusted EBITDA assist investors in comparing performance across reporting periods on a consistent basis by excluding items that management believes are not indicative of its operating performance. These non-GAAP measures are presented solely to allow investors to more fully assess the Company's results of operations and should not be considered in isolation of, or as substitutes for, an analysis of the Company's results as reported under U.S. GAAP.

The following are tabular presentations of adjusted earnings/loss and adjusted EBITDA, including a reconciliation from net earnings/loss, which the Company believes to be the most directly comparable U.S. GAAP financial measure.

Continuing	Discontinued	
<u>Operations</u>	Operations	Consolidated
Per	Per	Per

⁽a) Represents incremental direct costs incurred in connection with plant expansion projects and new product introductions before the project or product reaches normal production levels, including costs for the hiring and training of additional personnel, fees for outside services, travel costs, and plant- and production-related expenses. For 2023, start-up costs included in cost of goods sold related to the ramp-up of production at our new plant-based beverage facility in Midlothian, Texas, and the start-up of a new extrusion and high-speed packaging lines at our fruit snacks facility in Omak, Washington. For 2022, start-up costs included in cost of goods sold related to the hiring and training of new employees for the Midlothian facility together with costs related to the integration of the acquired Dream and West Life brands.

⁽b) Reflects costs, net of expected recoveries, related to the withdrawal of specific batches of aseptically-packaged product due to a faulty seal caused by an equipment misconfiguration by a third-party service provider. The equipment issue was identified and resolved in the third quarter of 2023, and none of the withdrawn product made it into the consumer marketplace.

		Share		Share		Share
For the quarters ended	\$	\$	\$	\$	\$	\$
December 30, 2023						
Net loss	(1,752)		(9,982)		(11,734)	
Dividends and accretion on preferred stock	(429)		_	_	(429)	
Loss attributable to common shareholders	(2,181)	(0.02)	(9,982)	(0.09)	(12,163)	(0.11)
Adjusted for:	2.440				2 440	
Product withdrawal costs(a) Exit from frozen fruit processing facility(b)	3,440		3,150		3,440 3,150	
Start-up costs(c)	2,394		-		2,394	
Frozen fruit inventory reserves(d)			1,900		1,900	
Loss on extinguishment of debt(e)	1,584		1,026		1,584 1,026	
Loss on divestiture of discontinued operations(f) Severance costs(g)	-		1,026		1,026	
Other(h)	491		617		1,108	
Net income tax on adjusting items(i)	-		-		-	
Adjusted earnings (loss)	5,728	0.05	(2,273)	(0.02)	3,455	0.03
rajusteu eurinigs (1855)	-					
December 31, 2022						
Net earnings (loss)	(427)		1,481		1,054	
Dividends and accretion on preferred stock	(830)		_	_	(830)	
Earnings (loss) attributable to common shareholders	(1,257)	(0.01)	1,481	0.01	224	0.00
Adjusted for: Start-up costs(c)	4,699				4,699	
Business development costs(j)	296		-		296	
Other(h)	243		(138)		105	
Net income tax on adjusting items(i)	(1,377)		(1,889)		(3,266)	
Adjusted earnings (loss)	2,604	0.02	(546)	(0.00)	2,058	0.02
Aujusteu eurinigs (1033)						

For the guarters ended	Continuing Operations \$	Discontinued Operations \$	Consolidated \$
December 30, 2023 Net loss Income tax expense (benefit) Interest expense (income), net Depreciation and amortization Stock-based compensation Adjusted for:	(1,752) (709) 7,518 8,166 2,789	(9,982) 469 (838) 25	(11,734) (240) 6,680 8,191 2,789
Product withdrawal and recall costs(a) Exit from frozen fruit processing facility(b) Start-up costs(c) Frozen fruit inventory reserves(d) Loss on divestiture of discontinued operations(f) Severance costs(g) Other(h)	3,440 2,394 - - - - 491	3,150 1,900 1,026 1,016 617	3,440 3,150 2,394 1,900 1,026 1,016 1,108
Adjusted EBITDA	22,337	(2,617)	19,720
December 31, 2022 Net earnings (loss) Income tax benefit Interest expense, net Depreciation and amortization Stock-based compensation	(427) (464) 4,312 6,219 4,139	1,481 (176) 418 2,939	1,054 (640) 4,730 9,158 4,139
Adjusted for: Start-up costs(c) Business development costs(j) Other(h) Adjusted EBITDA	4,699 296 243 19,017	- (138) 4,524	4,699 296 105 23,541

⁽a) Reflects costs, net of expected recoveries, of \$3.4 million related to the withdrawal of specific batches of aseptically-packaged product due to a faulty seal caused by an equipment misconfiguration by a third-party service provider, which are recorded in cost of goods sold.

⁽b) Reflects asset impairment charges and contract cancellation costs related to the exit from our Oxnard, California, frozen fruit processing facility in

connection with the divestiture of Frozen Fruit, which are recorded in loss from discontinued operations.

- (c) For the fourth quarter of 2023, start-up costs included the ramp-up of production at our new plant-based beverage facility in Midlothian, Texas, and the start-up of a new extrusion line at our fruit snacks facility in Omak, Washington, which are recorded in cost of goods sold. For the fourth quarter of 2022, start-up costs mainly related to the hiring and training of new employees for the Midlothian facility, which are recorded in cost of goods sold (\$4.6 million) and SG&A expenses (\$0.1 million).
- (d) Reflects inventory reserves recognized in connection with the divestiture of Frozen Fruit, which are recorded in loss from discontinued operations.
- (e) For the fourth quarter of 2023, we recognized a loss on the extinguishment of debt in connection with the refinancing of our credit agreement in December 2023, which is recorded in interest expense, net.
- (f) Reflects the pre-tax loss on the divestiture of Frozen Fruit, which is recorded in loss from discontinued operations.
- (g) Reflects severance costs of \$1.0 million for employees of Frozen Fruit that did not transfer as part of the divestiture, which are recorded in loss from discontinued operations.
- (h)For the fourth quarter of 2023, other includes a \$0.4 million loss on a foreign exchange hedge in connection with the divestiture of Frozen Fruit, which is recorded in other expense. For the fourth quarters of 2022 and 2023, other also reflects gains and losses on the disposal of assets, which are recorded in other expense and loss from discontinued operations.
- (i) Reflects the tax effect of the adjustments to earnings calculated based on the statutory tax rates applicable in the tax jurisdiction of the underlying adjustment, net of deferred tax valuation allowances. In addition, for the fourth quarter of 2022, includes \$1.9 million of tax benefits resulting from the settlement of the purchase price allocation related to the divestiture of Tradin Organic.
- (j) Represents third-party costs associated with business development activities, which are inclusive of costs related to the evaluation, execution, and integration of external acquisitions and divestitures, internal expansion projects, and other strategic initiatives. For the fourth quarter of 2022, these costs related to the divestiture of Frozen Fruit, which are recorded in SG&A expenses.

Share			Continuing Operations Per		Discontinued Operations Per		Consolidated Per
December 30, 2023 Ret loss (21,910)			Share		Share		Share
Net loss (21,910)		\$	\$	\$	\$	\$	\$
Adjusted for: Loss on divestiture of discontinued operations(a) Exit from frozen fruit inventory reserves(c) Exit from fruit incredien factors Exit from fruit ingredient processing facility(n) Exit from fruit ingredient processing facilit	Net loss Dividends and accretion on preferred stock	`(1,981)	(0.21)	-	(1.34)	(1,981)	(1.55)
Adjusted earnings (loss) December 31, 2022 Net earnings (loss) 3,881 (3,109) Earnings (loss) attributable to common shareholders Adjusted for: Loss on divestiture of discontinued operations(a) Start-up costs(b) Sale of frozen fruit processing facility(l) Business development costs(f) Exit from fruit ingredient processing facility(m) Net income tax on adjusting items(j) Adjusted for: 1,700 1,7305 1,7305 1,008 1,5721) (0.05) 3,978 (4,841) (6,722) (1,841) (1,8722) (1,841) (1,8722) (1,841) (1,	Adjusted for: Loss on divestiture of discontinued operations(a) Start-up costs(b) Frozen fruit inventory reserves(c) Exit from frozen fruit processing facility(d) Product withdrawal and recall costs(e) Business development costs(f) Loss on extinguishment of debt(g) Severance costs(h) Other(i) Net income tax on adjusting items(j)	20,249 - - 3,440 2,390 1,584 897	(-12-7)	119,821 12,900 10,014 2,500	(,	119,821 20,249 12,900 10,014 5,940 2,390 1,584 1,913	(1111)
Adjusted earnings (loss) 9,118 0.08 (5,721) (0.05) 3,397 0.03 December 31, 2022 Net earnings (loss) 3,881 (8,722) (4,841) Dividends and accretion on preferred stock Earnings (loss) attributable to common shareholders Adjusted for: Loss on divestiture of discontinued operations(a) Start-up costs(b) Sale of frozen fruit processing facility(l) Business development costs(f) Exit from fruit ingredient processing facility(m) Exit from fruit ingredient processing facility(m) Net income tax on adjusting items(j) 9,118 0.08 (5,721) (0.05) 3,397 0.03 (4,841) (3,109) - (3,109) - (3,109) - (0.08) (7,950) (0.07) (0.07) (0.07) (0.07) (0.07) (0.07) (0.08) (1,8722) (0.08) (1,8722) (0.08) (1,8722) (1,8724) (1,984) (3,978		-		3,978	
Net earnings (loss) 3,881 (3,109) (4,841) Dividends and accretion on preferred stock (3,109) - (3,109) Earnings (loss) attributable to common shareholders 772 0.01 (8,722) (0.08) (7,950) (0.07) Adjusted for: - 31,468 31,468 Start-up costs(b) 6,028 - 6,028 Sale of frozen fruit processing facility(l) - (2,544) (2,544) Business development costs(f) 1,170 - 1,170 Exit from fruit ingredient processing facility(m) 577 - 577 Other(i) 1,074 (202) 872 Net income tax on adjusting items(j) 7,305 0.07 1,607 0.02 3,803 0.08		9,118	0.08	(5,721)	(0.05)	3,397	0.03
Loss on divestiture of discontinued operations(a) - 31,468 Start-up costs(b) - 6,028 Sale of frozen fruit processing facility(l) - (2,544) Business development costs(f) 1,170 - 1,170 Exit from fruit ingredient processing facility(m) 577 - 577 Other(i) 1,074 (202) 872 Net income tax on adjusting items(j) (2,326) (18,303) (20,629)	Net earnings (loss) Dividends and accretion on preferred stock Earnings (loss) attributable to common shareholders	(3,109)	0.01	-	(0.08)	(3,109)	(0.07)
7.305 0.07 1.607 0.03 8.003 0.08	Loss on divestiture of discontinued operations(a) Start-up costs(b) Sale of frozen fruit processing facility(l) Business development costs(f) Exit from fruit ingredient processing facility(m) Other(i)	1,170 577 1,074		(2,544)		6,028 (2,544) 1,170 577 872	
	Adjusted earnings	7,295	0.07	1,697	0.02	8,992	0.08

11

	Continuing Operations	Discontinued Operations	Consolidated
For the years ended	\$	\$	\$
December 30, 2023 Net loss Income tax expense (benefit) Interest expense, net Depreciation and amortization Stock-based compensation Adjusted for:	(21,910) 3,269 26,909 31,039 11,778	(153,108) (167) 554 8,886	(175,018) 3,102 27,463 39,925 11,778
Loss on divestiture of discontinued operations(a) Start-up costs(b) Frozen fruit inventory reserves(c) Exit from frozen fruit processing facility(d) Product withdrawal and recall costs(e) Business development costs(f) Severance costs(h) Other(i)	20,249 - 3,440 2,390 897 471	119,821 12,900 10,014 2,500 1,016 1,136	119,821 20,249 12,900 10,014 5,940 2,390 1,913 1,607
Adjusted EBITDA	78,532	3,552	82,084
December 31, 2022 Net earnings (loss) Income tax expense (benefit) Interest expense, net Depreciation and amortization Stock-based compensation Adjusted for:	3,881 896 13,156 23,047 13,830	(8,722) (16,154) 1,578 14,626	(4,841) (15,258) 14,734 37,673 13,830
Loss on divestiture of discontinued operations(a) Start-up costs(b) Sale of frozen fruit processing facility(l) Business development costs(f) Exit from fruit ingredient processing facility(m) Other(i) Adjusted EBITDA	6,028 1,170 577 1,074 63,659	31,468 (2,544) - (202) 20,050	31,468 6,028 (2,544) 1,170 577 872

- (a) For 2023, reflects the pre-tax loss on the divestiture of Frozen Fruit, which is recorded in loss from discontinued operations. For 2022, reflects the pre-tax loss on the divestiture of Sunflower of \$23.2 million, together with a loss of \$8.2 million on the settlement of the purchase price allocation related to the 2020 divestiture of our global ingredients business, Tradin Organic, which are recorded in loss from discontinued operations.
- (b) For 2023, start-up costs included the ramp-up of production at our new plant-based beverage facility in Midlothian, Texas, the start-up of new extrusion and high-speed packaging lines at our fruit snacks facility in Omak, Washington, and professional fees related to productivity initiatives within our manufacturing operations, which are recorded in cost of goods sold (\$18.7 million) and SG&A expenses (\$1.5 million). For 2022, start-up costs mainly related to the hiring and training of new employees for the Midlothian facility, and the integration of the Dream and West Life brands, which are recorded in cost of goods sold (\$5.7 million) and SG&A expenses (\$0.3 million).
- (c) For 2023, reflects inventory reserves recognized in connection with the divestiture of Frozen Fruit, which are recorded in loss from discontinued operations.
- (d) For 2023, reflects asset impairment charges and contract cancellation costs related to the exit from our Oxnard, California, frozen fruit processing facility in connection with the divestiture of Frozen Fruit, which are recorded in loss from discontinued operations.
- (e) For 2023, reflects costs, net of expected recoveries, of \$3.4 million related to the withdrawal of specific batches of aseptically-packaged product due to a faulty seal caused by an equipment misconfiguration by a third-party service provider, which are recorded in cost of goods sold, as well as the self-insured retention amount of \$2.5 million under our insurance policies related to the recall of specific frozen fruit products initiated in the second quarter of 2023, which is recorded in loss from discontinued operations.
- (f) Represents third-party costs associated with business development activities, which are inclusive of costs related to the evaluation, execution, and integration of external acquisitions and divestitures, internal expansion projects, and other strategic initiatives. For 2023, business development costs related to the divestiture of Frozen Fruit, and, for 2022, these costs related to the divestitures of Frozen Fruit and Sunflower, together with our inaugural Investor Day held in June 2022. These costs are recorded in SG&A expenses.
- (g) For 2023, we recognized a loss on the extinguishment of debt in connection with the refinancing of our credit agreement in December 2023, which is recorded in interest expense, net.
- (h) For 2023, reflects employee severance costs of \$0.9 million recognized in connection with the consolidation of our continuing operations following the divestiture of Frozen Fruit, which are recorded in SG&A expenses, as well as severance costs of \$1.0 million for employees of Frozen Fruit that did not transfer as part of the divestiture, which are recorded in loss from discontinued operations.
- (i) For 2023, other includes a \$0.4 million loss on a foreign exchange hedge in connection with the divestiture of Frozen Fruit, which is recorded in other expense. For 2023 and 2022, other also reflects reserves for legal settlements and gains and losses on the disposal of assets, which are recorded in other expense/income and loss from discontinued operations.
- (j) Reflects the tax effect of the adjustments to earnings calculated based on the statutory tax rates applicable in the tax jurisdiction of the underlying adjustment, net of deferred tax valuation allowances. In addition, for 2022, includes \$12.9 million of tax benefits resulting from the settlement of

-

the purchase price allocation related to the divestiture of Tradin Organic.

- (k) For 2023, reflects an increase to the valuation allowance for U.S. deferred tax assets recognized in the second quarter of 2023, based on an assessment of the future realizability of the related tax benefits.
- (l) For 2022, reflects the gain on sale of a previously owned frozen fruit processing facility, net of exit costs, which is recorded in loss from discontinued operations.

(m) For 2022, reflects exit costs related to a former fruit ingredient processing facility, which are recorded in other expense.

Investor Relations:

Reed Anderson

ICR

646-277-1260

reed.anderson@icrinc.com

Source: SunOpta Inc.